$NWBO Up to date company activities and other important

New Post Public Reply Private Reply Replies (1) Message Board

Dec 14, 2013 at 10:38 AM

$NWBO Up to date company activities and other important information about $NWBO

$NWBO

DD Notes ~ http://www.ddnotesmaker.com/NWBO

##### recent news/filings ~ source: finance.yahoo.com

Fri, 13 Dec 2013 23:03:17 GMT ~ Nasdaq stocks posting largest volume increases
read full: http://sg.finance.yahoo.com/news/nasdaq-stock...nance.html
*********************************************************

Fri, 13 Dec 2013 23:02:55 GMT ~ Nasdaq stocks posting largest percentage increases
read full: http://sg.finance.yahoo.com/news/nasdaq-stock...nance.html
*********************************************************

Tue, 10 Dec 2013 13:15:00 GMT ~ First Interim Analysis Of NW Bio's Phase III GBM Trial Triggered By Reaching Required Number Of "Events"
- BETHESDA, Md., Dec. 10, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the number of events required to trigger the first interim analysis of its Phase III clinical trial in patients with Glioblastoma multiforme (GBM) brain cancer has been reached, and the analysis process is under way which will culminate in the independent Data Monitoring Committee's assessment. This important milestone is measured by "events," which are defined as either a tumor recurrence or a death. The pre-specified trigger number for this first interim analysis of NW Bio's international Phase III trial is 66 such events, comprising 60% of the 110 events required to reach the primary endpoint of the Phase III trial. Another interim analysis will occur when 88 events, comprising 80% of the total 110 events, have been reached.
read full: http://finance.yahoo.com/news/first-interim-a...00395.html
*********************************************************

Mon, 09 Dec 2013 14:29:44 GMT ~ Northwest Biotherapeutics: An Analysis Of Its Transforming Balance Sheet Restructuring
read full: http://seekingalpha.com/article/1885731-north...urce=yahoo
*********************************************************

Thu, 05 Dec 2013 13:15:00 GMT ~ Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
- BETHESDA, Md., Dec. 5, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that CEO Linda F. Powers will present at the Oppenheimer 24th Annual Healthcare Conference. The Conference will take place on December 10th and 11th at the Crowne Plaza Hotel in New York City. The Company will present on Tuesday, December 10, 2013, at 1:35 p.m. Investors interested in meeting one-on-one with senior management during the conference should contact their Oppenheimer representative or the Company. Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.
read full: http://finance.yahoo.com/news/northwest-bioth...00341.html
*********************************************************

##### chart ~ source: stockcharts.com

stockcharts.com/c-sc/sc?s=NWBO&p=D&b=5&g=0&id=p95448242713

##### chart ~ source: eoddata.com

http://chart.eoddata.com/?e=OTCBB&s=NWBO&...D&b=BB

##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NWBO/company-info
Ticker: $NWBO
OTC Market Place: Not Available
CIK code: 0001072379
Company name: Northwest Biotherapeutics, Inc.
Company website: http://www.nwbio.com
Incorporated In: DE, USA

##### extra dd links

Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/NWBO/filings
Latest financials: http://www.otcmarkets.com/stock/NWBO/financials
Latest news: http://www.otcmarkets.com/stock/NWBO/news - http://finance.yahoo.com/q/h?s=NWBO+Headlines

Major holdings: http://data.cnbc.com/quotes/NWBO/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=NWBO+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/NWBO.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=NWBO

RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search

DTCC: http://search2.dtcc.com/?q=Northwest+Biothera...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...ics%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.nwbio.com
Alexa: http://www.alexa.com/siteinfo/http://www.nwbio.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.nwbio.com

http://www.pennystocktweets.com/stocks/profile/NWBO

##### last known share structure ~ source: otcmarkets.com

Market Value: $137,472,400 a/o Dec 13, 2013
Shares Outstanding: 38,507,675 a/o Nov 12, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

##### business description ~ source: otcmarkets.com

Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company operates in the United States and is incorporated in Delaware, USA.

DD Notes ~ http://www.ddnotesmaker.com/NWBO

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vylor's $3 Billion Buyback: A Long-Term Bet

Pumping Confidence with a Massive Buyback Vylor's big move to throw $3 billion into a share buyback isn't about short-term antics. This company's doubling down on long-term value creation, making sure every stakeholder knows they're in for the long haul. It's a gutsy move but what this step really tells us is, they've got faith in the business and a balance sheet that can...

Anavex Faces Securities Lawsuit: Investor Implications

Storm Clouds Over Anavex: What Investors Need to Know If you've got a slice of Anavex Life Sciences Corp. (NASDAQ: AVXL) in your portfolio, the latest chapter of their legal saga feels less like a twist and more like a twist of the knife. These lawsuits often come out of left field for investors, but this one seems like a slow train that’s been gathering steam for a...

Tigo Energy Faces Class Action Over Revenue Claims

Trouble Brewing for Tigo Energy? Straight from the horse's mouth, we hear about Tigo Energy (NASDAQ: TYGO) getting embroiled in a class action smackdown. Picture it: Tigo fumbles their projections, and boy does it sting. They're caught in the crossfire for allegedly puffing up their revenue expectations tied to a venture with EG4 Electronics—poised to churn out...

WOLFX Super App Surges with 300% Growth Post-Launch

A Fast-Paced Entry into the College Scene College life isn’t getting any easier, but the WOLFX app is blazing a trail through U.S. campuses, promising to mend some of the chaos students deal with daily. It's barely taken a breath since launching just a month ago, already knitting itself into the routine of students from 104 universities in 130 cities across America -...

FuelCell's Class Action: Investors' Deadline Approaching

One Rough Ride for FuelCell Investors Sometimes the market feels like a roller coaster stuck on the down-hill plunge, and right now, FuelCell Energy (NASDAQ: FCEL) investors are gripping their harnesses. The latest turmoil has investors looking at a tight November 10 deadline to decide if they want in on the securities class action shaking the ground beneath FCEL. Looming...

Beyond The Bounce Expands with Pro Pickleball Star

Pickleball's Power Play: The Media Move Out of the blue, the world of niche sports finds its hub. Beyond The Bounce steps up to the plate by roping in pickleball’s own Zane Navratil. The hype’s not in the spin here—this is serious business. The company plans to push the boundaries of the sport into mainstream media, or at least give it a decent shot. Zane Navratil:...

HSG's Laser Tech Dazzles at FABTECH 2026

Laser Innovations on Display at FABTECH 2026 Listen up, folks—FABTECH 2026 in Vegas is where HSG Laser decided to flaunt their new toys, codenamed TS2 PRO and the mystical AI CutPilot. Now, unless you've been living under a rock, you'll know HSG is all about shaking up the laser cutting scene. They've done it for two decades, and now they're pushing the envelope with...

Volvo's Q3 2026 Results: Strong Growth and Margin

Volvo Group's Robust Q3 Performance It's not every day that you see a company like Volvo Group churning out results that make you take a second sip of that morning coffee. But here we are—looking at Q3 2026 with growth numbers that pack a punch. You can't argue with SEK 119.5 billion in net sales, especially when organic sales growth hit 7%. That's no small feat in...

Harbour BioMed's Batoclimab Injected Into Myasthenia Market

China's Green Light for Batoclimab When a new drug approval hits, particularly in a crucial market like China, it's a big deal. Harbour BioMed's recent go-ahead from the National Medical Products Administration (NMPA) for their Batoclimab injection is no exception. This marks the first full clinical cycle completion of an anti-FcRn treatment for generalized myasthenia...

3Srobotics Breaks Ground with North American Debut

3Srobotics Steps Into the Big League The sweltering buzz of FABTECH 2026 in Las Vegas signals more than just another industry tradeshow; it's the stage upon which 3Srobotics made its North American debut. In a span shorter than it takes most companies to get serious about their business cards, 3Srobotics has already nailed three funding rounds, snagging tens of millions...